Pfizer's free cash flow should improve. The drugmaker's lower leverage ratio target gives it greater financial flexibility.

Pfizer (PFE) stock and BioNTech (BNTX) stock in focus as FDA may not renew the authorization for their pediatric COVID shot. Read more here.